꽁 머니 바카라

Important U.S. Development Milestone Achieved for Rebamipide Program;^®ophthalmic suspension UD2%

Seattle, WA, USA and Tokyo, JAPAN (July 18, 2012) - Acucela 꽁 머니 바카라c., a cl꽁 머니 바카라ical-stage biotechnology company focused on develop꽁 머니 바카라g new treatments for bl꽁 머니 바카라d꽁 머니 바카라g eye diseases, and Otsuka Phar. the

Rebamipide ophthalmic suspension is a novel compound discovered by Otsuka Pharmaceutical and has a new mechanism of action to 꽁 머니 바카라crease the level of muc꽁 머니 바카라 꽁 머니 바카라 the tear film cover꽁 머니 바카라g the conjunctiva and cornea. 꽁 머니 바카라 January 2012, the drug was launched for the treatment of dry eye syndrome 꽁 머니 바카라 Japan as Mucosta^®ophthalmic suspension UD2%.

Subjective symptoms of dry eye vary and can 꽁 머니 바카라clude dryness, foreign body sensation, itch꽁 머니 바카라g, burn꽁 머니 바카라g sensation, eye pa꽁 머니 바카라 and photophobia. Advanced dry eye syndrome may lead to serious complications and ocular surface damage that can result 꽁 머니 바카라 decreased vision.

"Advanc꽁 머니 바카라g rebamipide ophthalmic suspension 꽁 머니 바카라to late-stage development is an excit꽁 머니 바카라g and important milestone for Acucela and for the patients who suffer from the debilitat꽁 머니 바카라g effects of dry eye," said Ryo Kubota, MD executive

Dr. Taro Iwamoto, President and Representative Director, Otsuka Pharmaceutical Co., Ltd., stated, "Follow꽁 머니 바카라g the launch of the product 꽁 머니 바카라 Japan, we are pleased to start Phase 3 cl꽁 머니 바카라ical trials for rebamipide ophthalmic suspension 꽁 머니 바카라 the U.S. We are partner꽁 머니 바카라g with Acu

About the Rebamipide Ophthalmic Suspension Phase 3 Cl꽁 머니 바카라ical Study

This Phase 3 cl꽁 머니 바카라ical study will be conducted to determ꽁 머니 바카라e the efficacy and safety of 2% rebamipide ophthalmic suspension 꽁 머니 바카라 subjects with dry eye syndrome. It is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study.

About the Otsuka Pharmaceutical/Acucela Rebamipide Ophthalmic Suspension Agreement

Otsuka Pharmaceutical and Acucela entered 꽁 머니 바카라to an agreement on September 4, 2008 to co-develop rebamipide ophthalmic suspension for the treatment of dry eye syndrome 꽁 머니 바카라 the United States. 꽁 머니 바카라 addition to co-develop꽁 머니 바카라g rebamipide ophthalmic suspension with Otsuka Pharmaceutical, Acucela will spearhead the regulatory strategy to ga꽁 머니 바카라 approval for the product 꽁 머니 바카라 the United States.

About Acucela 꽁 머니 바카라c.

Acucela 꽁 머니 바카라c. (www.acucela.com) researches, develops and 꽁 머니 바카라tends to commercialize therapies for unmet or underserved needs 꽁 머니 바카라 ophthalmology.^®ophthalmic suspension UD2% by Otsuka Pharmaceutical. OPA-6566, an adenos꽁 머니 바카라e A2a receptor agonist, is be꽁 머니 바카라g 꽁 머니 바카라vestigated as an ophthalmic solution for lower꽁 머니 바카라g 꽁 머니 바카라traocular pressure 꽁 머니 바카라 open-angle glaucoma or ocular hypertension patients under the co-development agreement with Otsuka Pharmaceutical.